• Ionis Pharmaceuticals EVP and Chief Clinical Development Officer Eugene Schneider sold 26,000 common shares on June 26.
• Sale priced at USD 81.05 per share; he also acquired 26,000 shares via option exercise at USD 60.89.
• Schneider held 77,114 Ionis shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000874015-26-000216), on June 30, 2026, and is solely responsible for the information contained therein.